Graybug Vision Inc (GRAY): Price and Financial Metrics

Graybug Vision Inc (GRAY): $0.62

-0.01 (-1.57%)

POWR Rating

Component Grades













GRAY Stock Price Chart Interactive Chart >

Price chart for GRAY

GRAY Price/Volume Stats

Current price $0.62 52-week high $2.33
Prev. close $0.63 52-week low $0.60
Day low $0.62 Volume 13,900
Day high $0.64 Avg. volume 211,408
50-day MA $0.92 Dividend yield N/A
200-day MA $1.02 Market Cap 13.37M

Graybug Vision Inc (GRAY) Company Bio

GrayBug is a pharmaceutical company that focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. The company is currently developing a continuum of proprietary micro – and nanoparticle controlled release technologies and implants for strategic partnership and its own therapeutic products for major ocular disease indications including wet AMD and Glaucoma. The company was founded in 2011 and headquartered in Baltimore, Maryland.

GRAY Latest News Stream

Event/Time News Detail
Loading, please wait...

GRAY Latest Social Stream

Loading social stream, please wait...

View Full GRAY Social Stream

Latest GRAY News From Around the Web

Below are the latest news stories about GRAYBUG VISION INC that investors may wish to consider to help them evaluate GRAY as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to start the day with an overview of the biggest pre-market stock movers traders need to know about for Tuesday morning!

William White on InvestorPlace | November 22, 2022

Graybug Vision Agrees To Merge With Inflammatory Disease-Focused Biopharma

Graybug Vision Inc (NASDAQ: GRAY) and CalciMedica Inc (CalciMedica) have announced a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will further develop CalciMedica's lead product candidate Auxora for inflammatory diseases, such as acute pancreatitis, asparaginase-associated pancreatitis, acute kidney injury, and acute hypoxemic respiratory failure. Auxora, which modulates the immune response and protects against tissue cell injury, has bee

Yahoo | November 22, 2022

Graybug and CalciMedica Enter into Definitive Merger Agreement

– Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica’s pipeline of first-in-class product candidates for life-threatening inflammatory diseases – Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into the second half of 2024 – Phase 2b results in acute pancreatitis for lead product candidate Auxora expected in second half of 2023 – Companies will host joi

Yahoo | November 21, 2022

Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022

REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focused historically on developing transformative medicines for ocular diseases, today reported financial results for the three and nine months ended September 30, 2022. Financial Results for the Three Months Ended September 30, 2022 Net loss for the quarter ended September 30, 2022 was $9.8 million compared to $8.0 million for the s

Yahoo | November 10, 2022

Analysts Offer Insights on Healthcare Companies: Axcella Health (AXLA) and Graybug Vision (GRAY)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Axcella Health (AXLA – Research Report) and Graybug Vision (GRAY – Research Report). Axcella Health (AXLA) In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Axcella Health, with a price target of $9.00. The company's shares closed last Friday at $2.33. According to TipRanks.

Christine Brown on TipRanks | August 15, 2022

Read More 'GRAY' Stories Here

GRAY Price Returns

1-mo -36.08%
3-mo -35.82%
6-mo -36.88%
1-year -70.48%
3-year N/A
5-year N/A
YTD -66.12%
2021 -93.69%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5825 seconds.